 |
| |
|
|
| 09:00 - 09:45 |
Greetings
Prof. Michael Sela
Chairman of the Conference. |
Hall A |
|
|
Opening
Mr. Ehud Olmert
Vice Prime Minister, Minister of Industry, Trade and Labor |
|
| |
Plenary Session I
Chairperson: Prof. Haim Aviv
Pharmos Ltd. |
|
| |
Walking the tightrope
Prof. Charles Weissmann, National Hospital
For Neurology and Neurosurgery, London, UK |
|
| |
|
|
|
10:00 - 11:00
|
Plenary Session II
Chairperson: Mr. Claudio Yarza
Partner in charge of Life Sciences Practice, PricewaterhouseCoopers
Kesselman & Kesselman |
Hall A
|
| |
State of the Industry and
Global Trends
Dr. Ben Chen, Director, Burrill & Company,
Strategic Partnering Services
Mr. Tracy T. Lefteroff, Global Managing Partner, Life Sciences
Industry Services, Private Equity and Venture Capital, PricewaterhouseCoopers
LLP |
|
| |
|
|
|
11:30 - 13:00
|
S01: GENES & DISEASES
Chairperson: Prof. Rivka Carmi,
Ben Gurion University of The Negev |
Hall A
|
| |
ATM: from disease to gene,
to protein - and back
Prof. Yossi Shiloh, Tel-Aviv University |
|
| |
From human population to animal
model - the story of the Bardet-Biedl syndrome
Prof. Val C. Sheffield, University of Iowa |
|
| |
The molecular basis regulating
the response of patients to aminoglycoside treatment
Prof. Batsheva Kerem, The Hebrew University
of Jerusalem |
|
| |
Mendelian diseases in Israel
- medical and research perceptions
Prof. Joel Zlotogora, Sheba Medical Center |
|
| |
|
|
|
11:30 - 13:00
|
SE01: Panel I
GETTING DEALS DONE WITH PHARMA:
TIPS FROM THE LEADERS
Chairperson: Mr. Jeffrey M. Wiesen, Member, Chairman
of the Biotechnology
Practice, Mintz, Levin, Cohn, Ferris, Glovsky and Popeo P.C.
|
Hall B
|
| |
Ms. Tamar
D. Howson , Senior Vice President, Corporate and Business Development,
Bristol-Myers Squibb
Mr. Jeremy Levin, Dphil, Global Head of Strategic Alliances,
Novartis Institutes for Biomedical Research |
|
| |
|
|
|
14:30 - 16:00
|
S10: NEUROBIOLOGY
Chairperson: Prof. Rafi Mechoulam,
The Hebrew University of Jerusalem |
Hall A
|
| |
Targeting intracellular pathways
as a novel approach to the treatment of traumatic brain injury
Prof. Esther Shohami, The Hebrew University
of Jerusalem |
|
| |
T cell-based vaccination for
slowing down progression of neurodegenerative disorders
Prof. Michal Schwartz, The Weizmann Institute
of Science |
|
| |
Multi-functional drugs for
various CNS targets in the treatment of neurodegenerative diseases
Prof. Moussa B.H. Youdim, Technion - Israel
Institute of Technology |
|
| |
The potential use of AD4 for
the treatment of neurodegenerative diseases such as Alzheimer's, Parkinson’s
and multiple sclerosis
Prof. Daphne Atlas, The Hebrew University
of Jerusalem |
|
| |
|
|
|
14:30 - 16:00
|
SE02: Panel II
THE ISRAELI BIOTECH INDUSTRY: CHALLENGES AND OPPORTUNITIES
Moderator: Mr. Avner Lushi, CEO, Life Sciences Transaction
Support (LTS) |
Hall B
|
| |
Ms. Aviva
Mishmari, Journalist
Dr. Dov Kanner, Managing Director, Bio-Technology General (Israel),
Executive Vice President/Chief Technical Officer, Savient Pharmaceuticals
Dr. Zachi Berger, Investment Manager, Healthcare, Star Ventures
Dr. Ilan Cohn, President & CEO, Can-Fite Biopharma
Dr. Yuval Binur, Chairman, Accelerated Technologies, Managing
General Partner, Medica Venture Partners
Dr. Morris Laster, CEO, BioLineRX |
|
| |
|
|
|
16:30 - 18:00
|
S03: FUTURE CHALLENGES IN BIOTECHNOLOGY
Chairperson: Prof. Michael Sela,
The Weizmann Institute of Science |
Hall A
|
| |
The brave new world of Biotech:
The human being, his genes and his ethics
Prof. Michel Revel, The Weizmann Institute
of Science |
|
| |
The need for a new understanding
Dr. Martin Gerstel, Compugen Ltd. |
|
 |
The challenge of Biotech: The
future ain’t what it used to be
Dr. Aharon Schwartz, Teva Pharmaceutical
Industries |
|
